B&L launches Stellaris Vision Enhancement System

Article

Bausch & Lomb (B&L) today launched its new Stellaris Vision Enhancement system, further demonstrating its dedication to its microincision cataract surgery franchise.

Bausch & Lomb (B&L) today launched its new Stellaris Vision Enhancement system, further demonstrating its dedication to its microincision cataract surgery franchise.

Following on from the successes of the Millennium Microsurgical System and the Akreos acrylic intraocular lenses (IOLs), Stellaris offers surgeons the opportunity to perform both biaxial and coaxial microincision cataract surgery (B-MICS and C-MICS, respectively) procedures through a 1.8 mm incision.

According to the firm, the Stellaris EQ fluidics management technology allows surgeons to choose either a flow-vacuum module (AFM) or an advanced vacuum module (AVM). It also allows them to switch between the two for greater flexibility, stability and efficiency.

Additional features include the new ergonomically-designed, six-crystal phaco handpiece, Bluetooth wireless-enabled dual-linear foot pedal, and high-definition touch-screen display.

"With the launch of the Stellaris Vision Enhancement System and our Akreos MI60 microincision lens, we are poised to further enhance our leadership position," said Alan Farnsworth, B&L corporate senior vice president and president, Europe, Middle East and Africa Region.

According to H. Burkhard Dick, MD of Universitäts-Augenklinik, Center for Vision Science, Ruhr University, Germany, who has used the Stellaris system in more than 50 cases, it offers good performance, control and versatility. Meanwhile, he feels the optimized cutting deals with even the hardest nuclei whilst the improved fluidics contribute greatly to chamber stability when performing both biaxial and microcoaxial phaco.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.